We can treat alzheimer's disease successfully in mice but not in men: Failure in translation? A perspective

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 147-150

  Windisch, Manfred ^a  

^a NeuroScios GmbH   (Austria)

Author keywords

Amyloid ; Behavior; Pathology; Tau protein; Transgenic technology; Translational methods

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; MEMANTINE;

ALZHEIMER DISEASE; ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ETIOLOGY; HUMAN; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RODENT MODEL; TRANSGENIC ANIMAL; ANIMAL MODEL; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG PROGRAM; EXPERIENCE; EXPERIMENTATION;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MICE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896734453     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000357568     Document Type: Article

References (13)

1. Li C, Ebrahimi A, Schluesener H: Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. Ageing Res Rev 2013; 12: 116-140.
2. Windisch M, Flunkert S, Havas D, Hutter-Paier B: Commentary to the recently published review 'Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease' by Li, Evrahimi and Schluesener. Ageing Res Rev 2013; 12: 116-140.
3. Ageing Res Rev 2013; 12: 852-854.
4. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J Neuroinflamm 2004; 1: 24.
5. Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA: Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 2008; 28: 1537-1545.
6. 11 C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascendingdose study, Lancet Neurol 2010; 9: 363-372.
7. Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, Ottonello S, Leon A: In vitro and in vivo profiling of CHF5022 and CHF5074, two beta-amyloid 1-42 lowering agents. Pharmacol Res 2007; 55: 318-328.
8. Lanz TA, Fici GJ, Merchant KM: Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 2005; 312: 399-406.
9. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N: Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice, J Neurosci 2012; 32: 2037-2050.
10. Zahs KR, Ashe KH: 'Too much good news'-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 2010; 33: 381-389.
11. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T: A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci 2013; 33: 6245-6256.
12. Shuaib A: Neuroprotection-STAIR-way to the future? Cerebrovasc Dis 2006; 22: 10-17.
13. Loffler T, Flunkert S, Havas D, Santha M, Hutter-Paier B, Steyrer E, Windisch M: Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging 2013; 34: 2379-2388.